Introduction {#sec1}
============

Obesity is associated with many cardiovascular (CV) risk factors such as hypertension, type 2 diabetes (T2D), dyslipidemia, and systemic inflammation ^\[^ [@bib1], [@bib2], [@bib3], [@bib4] ^\]^. The long-term consequences of these risk factors are increasingly recognized, and CV diseases such as heart failure, atrial fibrillation, coronary artery disease, but also valvular heart disease and stroke are common, particularly in the elderly. Obesity has become one of the largest healthcare problems worldwide. The prevalence of obesity (i.e. body mass index \[BMI\] ≥ 30 kg/m^2^) is currently around 40%, and is still increasing ^\[^ [@bib5] ^\]^. As a result, obesity is increasingly recognized as a serious, and potentially treatable risk factor for CV disease [@bib1] ^,^ [@bib2].

Treatment of obesity is difficult, and currently, bariatric surgery is the only treatment option that renders significant and durable weight loss in obese patients with relatively low peri- and post-operative complications rates ^\[^ [@bib6], [@bib7], [@bib8] ^\]^. Anastomotic leakage and bleeding are the most common reported complications early after surgery, but vascular or cardiopulmonary problems can also occur ^\[^ [@bib9] ^\]^. The latter were reported to be present in up to 1.3% of all bariatric patients ^\[^ [@bib9] ^\]^, although a larger study showed that during 90-day follow-up the percentage of CV deaths was much higher compared to those caused by leakage or bowel obstruction: 10/36 deaths were "heart related" (28%), and strongly related to CV risk factors and increasing age ^\[^ [@bib8] ^\]^. Although the majority of patients undergoing bariatric surgery are relatively young, a significant proportion of patients is older than 50 years of age, and these patients have a risk for CV diseases ^\[^ [@bib10] ^\]^. Given the significant number of patients with CV disease who will undergo bariatric surgery, screening for subclinical or unrecognized CV disease in patients ≥50 years may be beneficial.

Despite several review articles that have described possible diagnostic procedures in patients who undergo bariatric surgery, current bariatric guidelines do not provide details regarding preoperative cardiac work-up [@bib6] ^,^ [@bib11] ^,^ [@bib12].

In the present study, we therefore aimed to determine the prevalence and incidence of CV diseases in patients ≥50 years who were undergoing bariatric surgery. Because cardiac examinations are not routinely performed in patients referred for bariatric surgery, we investigated whether a simple marker could provide useful information. Therefore, we measured N-terminal pro Brain Natriuretic Peptide (NT-proBNP) levels in consecutive patients ≥50 years old who were scheduled to undergo bariatric surgery. This biomarker is one the most sensitive markers to detect early CV disease ^\[^ [@bib13] ^\]^, and has proven to be of important diagnostic value in patient groups undergoing non-cardiac (vascular) surgery [@bib14] ^,^ [@bib15].

Methods {#sec2}
=======

All patients in the present study were referred to the Department of Bariatric Surgery, Rijnstate Hospital; Arnhem; the Netherlands, between June 2019 and January 2020, which is a high-volume bariatric center performing around 1300 bariatric procedures per year. For this prospective cohort study, only patients who were ≥50 years old, and who fulfilled the IFSO criteria (BMI ≥ 35 kg/m^2^ with an obesity related comorbidity or BMI ≥40 kg/m^2^), were considered eligible.

The cardiac screening protocol was approved by the Local Ethics Committee, and all patients gave informed consent. The present study was in concordance with the principles outlined in the Declaration of Helsinki. In patients who were deemed eligible, plasma NT-proBNP samples were collected and NT-proBNP concentrations in blood samples were measured by the Atellica® IM PBNP Essay, using the Atellica IM Analyzer (Siemens Healthineers, Erlangen, Germany). If the NT-proBNP value was 125 pg/ml or higher, patients were referred to the Department of Cardiology, Rijnstate Hospital for further cardiac work-up. This cut-off point is advocated by the European Society of Cardiology (ESC) for excluding heart failure. Although several confounders for NT-proBNP levels are known, including age, fat mass, and sex, this cut-off point has been shown to provide a reasonable performance [@bib16] ^,^ [@bib17].

If patients were referred to the cardiologist, a 12-lead standard electrocardiogram (ECG) was performed, as well as an echocardiogram. Transthoracic 2- and 3-Dimensional echocardiography was performed using Epiq Philips (EPIQ 7C Hardware en software version 5.02). HeartModel software was used to measure left ventricular (LV) and left atrial global volume at end-diastole and at end-systole, and to calculate the left ventricular ejection fraction (LVEF). All measurements were assessed according to the current recommendations for cardiac chamber quantification and assessment of diastolic function ^\[^ [@bib18] ^\]^, and included LV systolic function (in particular LVEF), tricuspid annular plane systolic excursion for right ventricular function, and left ventricular diastolic function (E, A, E/A ratio, e', and E/e' ratio), valvular stenosis and/or regurgitation, and the peak pressure gradient across the tricuspid valve. Left atrial enlargement was defined as ≥34 ml/m^2^, LV hypertrophy as LV mass index \>95g/m^2^ for women and \>115g/m^2^ for men, and diastolic dysfunction as mean septal and lateral 'e \<9cm/s and/or E/e' \>13, all according to the current ESC criteria ^\[^ [@bib19] ^\]^.

Heart failure was documented if patients had LVEF \<40% ("heart failure with reduced LVEF, or systolic heart failure"), or LVEF 40-49% ("heart failure with mid-range EF"), or if they fulfilled the criteria of heart failure with preserved LVEF, i.e. ≥50%, and additional echocardiographic evidence for relevant structural heart disease, including LV hypertrophy and/or left atrial enlargement and/or diastolic dysfunction, as described earlier in this section. ^\[^ [@bib19] ^\]^.

Besides electrocardiography and echocardiography, additional diagnostic tests or interventions were performed when deemed necessary. Adverse events during the first 30 days after surgery were documented. We had particular interest in cardiovascular and pulmonary adverse events, including severe arrhythmias, acute heart failure, acute coronary syndrome, stroke or transient ischemic attack, pneumonia, deep vein thrombosis or pulmonary embolism, acute renal failure and reintubation. Severity of adverse events were scored according to the Clavien Dindo Classification, minor and major complications were respectively defined as class 1-2 and class ≥3A ^\[^ [@bib20] ^\]^.

Normally and non-normally distributed data were described using means with standard deviations (SD) and medians with interquartile ranges (IQR). Continuous data were analyzed using independent t-tests, Mann Whitney U test or a Fishers' exact test, depending on the distribution. A *p* value of \< 0.05 was considered as statistically significant. Statistical analyses were performed by using IBM SPSS Statistics, version 25.0 for Windows (SPSS. Chicago, IL).

Results {#sec3}
=======

Patient characteristics {#sec3.1}
-----------------------

Between June 2019 and January 2020, NT-proBNP levels were assessed in 310 consecutive patients referred for bariatric surgery ([Figure 1](#fig1){ref-type="fig"} ). The median age of patients was 56 years, 72% were female, and mean BMI was 42.6 kg/m^2^. Patients had a high prevalence of CV risk factors such as hypertension (58%), dyslipidemia (35%) and T2D (28%) ([Table 1](#tbl1){ref-type="table"} ).Figure 1Distribution of NT-proBNP levels . NT-proBNP N-terminal-pro hormone brain natriuretic peptide, CVD cardiovascular diseaseTable 1Baseline characteristics and postoperative outcomesTotal, N=310Elevated NT-proBNP N=72Normal NT-proBNP, N=238p-value**Age** (median, IQR) \*55,9 (53-61)57 (54-62)56 (53-60)0.406**Gender, female** (n,%)224 (72.3)57 (79.2)167 (70.2)0.088**BMI** (mean, SD)42,6 ±6.543,7 ±7.842,1 ±6.00.445**Abd. Circumference** (mean, SD)128 ±13127 ±15128 ±130.171**Smoking** (n,%)0.828•Current smoking21 (6.8)6 (8.3)15 (6.3)•History of smoking151 (48.7)34 (47.2)117 (49.2)**Medical history** (n,%)•Hypertension179 (57.7)47 (65.3)132 (55.5)0.173•Hypercholesterolemia107 (34.5)26 (36.1)81 (34)0.425•Diabetes88 (28.4)18 (25)70 (29.4)0.312•Obstructive Sleep Apnea84 (27.1)18 (25)66 (27.7)0.272•Chronic Kidney Disease13 (4.2)8 (11.1)5 (2.1)0.003•Chronic Obstructive Pulmonary Disease19 (6.1)7 (9.7)12 (5)0.163**History of cardiovascular disease**(n,%)\*64 (20.6)30 (41.7)34 (14.3)\<0.001•Atrial Fibrillation27 (8.7)17 (23.6)10 (4.2)\<0.001o History of AFrowhead20 (6.4)10 (13.9)10 (4.2)o Current AFrowhead7 (2.3)7 (9.7)0•Heart Failure (n,%)6 (1.9)5 (6.9)1 (0.4)0.003•Coronary artery diseases31 (10)9 (12.5)22 (9.2)0.126o Angina Pectoris / no significant abnormalities on CAGrowhead13 (4.2)5 (6.9)8 (3.4)o MI / PCI / CABGrowhead18 (5.8)4 (5.6)14 (5.9)•Valvular disease6 (1.9)3 (4.2)3 (1.3)0.140•Other cardiovascular disease5 (1.6)2 (2.8)3 1.3)0.330**Medications**•ACEI or ARB144 (46.5)42 (58.3)102 (42.9)0.023•Beta-blocker81 (26.1)30 (41.7)51 (21.4)0.001•Diuretics102 (32.9)31 (43.1)71 (29.8)0.045•Lipid lowering agents109 (35.2)27 (37.5)82 (34.5)0.673•Oral anticoagulants24 (7.7)13 (18.1)11 (4.6)0.001•Platelet aggregation inhibitors48 (15.5)9 (12.5)39 (16.4)0.464•Insulin33 (10.6)7 (9.7)26 (10.9)0.772•GLP-1 agonist11 (3.5)3 (4.2)8 (3.4)0.180•Oral antidiabetic drugs73 (23.5)13 (18.1)60 (25.2)0.267**Procedure**266 (85.8)57 (79.2)209 (87.8)0.646•LRYGB223 (83.8)46 (80.7)177 (84.7)•LSG26 (9.8)6 (10.5)20 (9.6)•Conversion LAGB to LRYGB14 (5.3)4 (7.0)10 (4.7)•Conversion LAGB to LSG2 (0.8)02 (1.0)•Conversion LSG to SADI1 (0.4)1 (1.8)0[^2][^3]

Elevated NT-proBNP levels were observed in 72 patients (23%), the distribution of NT-proBNP levels is shown in [Figure 1](#fig1){ref-type="fig"}. A history of CV disease was present in 64 of the 310 patients (21%) ([Table 1](#tbl1){ref-type="table"}). Patients with elevated NT-proBNP levels more often had a history of CV disease (42% vs 14%) and also used more CV drugs. There were 31 patients with a history of coronary artery disease, but in general NT-proBNP levels were not increased in these patients. A history of atrial fibrillation was present in 22 patients, and 17 of them had elevated NT-proBNP levels. A history of heart failure was present in only six patients and five of them had elevated NT-proBNP levels. Use of CV drugs, in particular angiotensin converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers and diuretics was more common in patients with elevated NT-proBNP compared to patients with normal NT-proBNP values (all p\<0.05) . Of the 72 patients who had elevated NT-proBNP levels, 67 patients were referred for further cardiac work-up ([Figure 2](#fig2){ref-type="fig"} ). Two patients dropped out of the study (one patient with a BMI of 83 kg/m^2^ who was not considered eligible for surgery, and one was lost to follow-up). In three other patients in whom NT-proBNP was marginally increased (between 125 and 150 pg/ml) further cardiac work-up was not performed at the discretion of the treating physician.Figure 2Distribution of LVEF in patients who underwent preoperative echocardiography *LVEF* left ventricular ejection fraction

Findings during cardiac work-up {#sec3.2}
-------------------------------

Of the 67 patients who were referred for further cardiac work-up, current atrial fibrillation/flutter was observed in seven patients on their ECG, which was in line with their medical history. In addition, eight patients had a history of these arrhythmias, but were in sinus rhythm on ECG.

On echocardiography, three of the 67 patients had systolic dysfunction, i.e. LVEF \<40%, and nine patients had a LVEF of 40-49%, i.e. mild systolic dysfunction, whereas the majority of patients had LVEF ≥50%. 25 of 67 patients (37%) had evidence of structural and/or functional abnormalities on echocardiography. Only four of these 25 patients had a previous medical history of "heart failure".

Of the 55 patients with LVEF ≥ 50%, 13 had evidence for structural heart disease on echocardiography: left atrial enlargement (n=9), left ventricular hypertrophy (n=4), and/or evidence of diastolic dysfunction (n=3; patients may have more than one criterion). Using our work-up, this means that the observed increased NT-proBNP levels in concert with the echo data, resulted in newly found biochemical and echocardiographic evidence for heart failure with preserved ejection fraction (HFPEF) ^\[^ [@bib19] ^\]^ in 13 of these 55 patients ([Figure 3](#fig3){ref-type="fig"} ).Figure 3Flowchart and main outcomes of cardiac preoperative evaluation \* 'Normal' was defined as 'no significant abnormalities found on echocardiogram' following current ESC guidelines \*\* Patients may have more than one criterion *NT-proBNP* N-terminal-pro hormone brain natriuretic peptide, *LVEF* left ventricular ejection fraction, *LV* left ventricle

In six of the 67 patients, additional diagnostic tests were done. One patient with a history of coronary artery bypass surgery had recurrent cardiac events of chest pain and myocardial ischemia, and underwent percutaneous coronary intervention. In two additional patients, coronary angiography was performed, which showed no coronary lesions, but both were found to have heart failure. Three patients had abnormalities on ECG, which led to 24-hour Holter ECG in two of them, and a cardiac MRI in the other, none of these three patients was diagnosed with a new CV disease. All six patients were subsequently accepted for surgery.

As a result of cardiac work-up, cardiovascular drug regimens were adjusted in nine patients. in seven patients, new drugs were prescribed (diuretics n=2, statins n=2, beta blocker n=1, ACE-inhibitor n=1, calcium channel blocker n=1). In the remaining two patients, adjustment of beta blocker dosage was instructed for one, and a diuretic was ceased in another. In five other patients, the treating cardiologist ordered perioperative instructions on cardiovascular drugs, fluid balance or oral anticoagulants.

Surgical outcome {#sec3.3}
----------------

Of the 310 patients, 266 patients underwent bariatric surgery. In patients with an increased NT-proBNP, 57 of the 72 patients were operated, whereas 209 of the 238 with normal NT-proBNP were operated. Of the 44 non-operated patients, surgery was either cancelled (n=12) or postponed (n=32). Reasons for postponement of surgery were: need for further lifestyle changes or psychological management (n=10), additional cardiac work-up (n=2), and the covid-19 pandemic (n=20). During 30-day follow-up, no cardiac adverse events occurred. Total adverse events were found in four patients with elevated NT-proBNP levels, and in 15 with normal NT-proBNP levels, 7.0% and 7.2%, respectively, and none had a fatal outcome. Major adverse events occurred only in the group with normal NT-proBNP levels (5 of 209 patients; 2.4%), and were all surgical complications: stenosis of jejunojejunostomy (n=2), postoperative hemorrhage (n=1), anastomotic leakage (n=1), internal herniation (n=1).

Discussion {#sec4}
==========

The main purpose of this study was to determine the prevalence and incidence of subclinical or unrecognized CV disease in patients ≥50 years scheduled for bariatric surgery using plasma NT-proBNP. NT-proBNP was increased in 72 (23%) of the 310 patients. Of the 67 patients who underwent thorough cardiac evaluation, echocardiographic evidence of structural and/or functional remodeling was present in 25 patients (37%), and only four of these 25 patients had a medical history of heart failure. This means that this non-invasive, simple and cheap diagnostic tool could be used to detect new of structural and/or functional remodeling in a high-risk patient population that is evaluated for bariatric surgery.

Natriuretic peptides such as NT-proBNP and brain natriuretic peptide (BNP) are most often used for monitoring patients with established heart failure, and both have important clinical and prognostic value for long-term outcome ^\[^ [@bib21] ^\]^. In addition, these biomarkers are powerful tools to predict new onset heart failure ^\[^ [@bib22] ^\]^. Interestingly, in addition to heart failure and atrial fibrillation, NT-proBNP levels also strongly predict other CV events, such as myocardial infarction and stroke ^\[^ [@bib23] ^\]^. Therefore, NT-proBNP could be a reliable screening tool for CV disease. However, in our results we mainly observed elevated plasma NT-proBNP in patients with heart failure or atrial fibrillation, and to a lesser extend in patients with coronary artery disease. Therefore, the use of NT-proBNP as a screening tool for CV diseases may be best used for new-onset heart failure.

NT-proBNP and BNP have been evaluated for their prognostic value as cardiac screening tools to predict the development of (major) cardiac events [@bib14] ^,^ [@bib24]. In our cohort, no CV events occurred in the postoperative phase, though unlikely, this might have been influenced by alterations in CV drugs during cardiac work-up. In general, there is limited data available on the incidence of cardiac complications following bariatric surgery, but in general the incidence is low, ranging between 0.1-1.7% [@bib25] ^,^ [@bib26]. So far, no studies have examined the association between pre-operative cardiac screening and outcome after bariatric surgery. Two meta-analyses concluded that single preoperative measurements of either NT-proBNP or BNP are both good predictors for cardiovascular complications [@bib14] ^,^ [@bib24]. These meta-analyses examined patients that were undergoing non-cardiac surgery, and several studies did evaluate patients undergoing (major) abdominal procedures, but not specifically patients undergoing bariatric surgery. Procedures that were examined in these meta-analyses were mainly classified as high risk for development of cardiac complications, while bariatric surgery is classified as a procedure with intermediate risk ^\[^ [@bib14] ^\]^. Elevated BNP or NT-proBNP levels were associated with an increased risk for the development of cardiovascular complications (odds ratio of 19.3 \[95% CI 8.5-43.7\]) ^\[^ [@bib24] ^\]^, and an area under the curve (AUC) of the relative operating characteristic (ROC) for the predictive value of elevated BNP or NT-proBNP levels was 0.70 (95% CI 0.66 - 0.74) ^\[^ [@bib14] ^\]^. In a more recent prospective study including more procedures with an intermediate risk of cardiac complications, the AUC was 0.88 (95% CI 0.82-0.93) for preoperative NT-proBNP measurements ^\[^ [@bib27] ^\]^. Outcomes consistently show that heart failure is an independent predictor for major adverse cardiac events (MACE) ^\[^ [@bib28] ^\]^. As an alternative for a single measurement screening tool for major cardiac adverse events, several risk assessment tools have been tested in non-cardiac surgery patients, such as the 6-item Revised Cardiac Risk Index that indicates whether preoperative cardiac assessment should be performed ^\[^ [@bib29] ^\]^. Two newer prediction models are available as online tools for risk assessment of MACE and integrate 23 and 30 items [@bib30] ^,^ [@bib31]. However, none of these prediction tools are validated in bariatric study patients and might not be sensitive enough. Given the lack of a validated screening tool for CV disease and high prevalence of occult LV dysfunction (and heart failure) in our cohort, it is somewhat surprising that in the recently reported Clinical Practice Guidelines for patients undergoing Bariatric Surgery, standard preoperative evaluation of (high risk) patients in order to detect occult CV disease -in selected patients- is also not discussed ^\[^ [@bib6] ^\]^.

With current acceptably low morbidity and mortality rates in the early phase after bariatric surgery, and the evident long-term improvements in weight loss and CV disease, it is likely that the number of patients eligible for bariatric surgery will further increase. Moreover, it is conceivable that obese patients with specific CV diseases such as heart failure and atrial fibrillation, will be considered candidates for bariatric or metabolic surgery, not just to induce weight loss, but specifically to treat these comorbidities ^\[^ [@bib6] ^\]^. Especially for these patients at high-risk of developing CV complications, accurate pre-operative CV screening is important. Therefore, NT-proBNP assessment could prove to be the first choice as a screening tool, since it is cheap, easy and non-invasive.

There are some limitations that merit emphasis. First, this is a single center study with a relatively small sample size. Therefore, the results may not provide conclusive evidence whether cardiac screening is beneficial, in terms of reducing CV morbidity and mortality. Second, patients with normal NT-proBNP levels were not referred for ECG or echocardiography, therefore the presence of CV disease is unknown in these patients. However, it has been established that a normal BNP or NT-proBNP makes it very unlikely that a patient has CV disease, especially heart failure ^\[^ [@bib19] ^\]^. It should also be noted that NT-proBNP is a stronger predictor for heart failure than coronary artery disease and stroke, albeit we did identify two patients in our cohort that required intervention for coronary artery disease while using NT-proBNP [@bib13] ^,^ [@bib23]. Third, the aim of our study was to examine the value of NT-proBNP as a screening tool for CV disease, and was consequently not powered to examine a potential association with post-operative cardiovascular outcome. Fourth, NT-proBNP has an inverse relation with BMI ^\[^ [@bib32] ^\]^, which means that patients with potential CV disease could have false negative outcome of cardiac screening with NT-proBNP. This implies that the reported 23% of patients with elevated NT-proBNP in our study is probably an underestimation of the actual number of patients with CV disease. Fifth, use of NT-proBNP as a single screening tool might be less predictive for CV disease than a prediction model that combines NT-proBNP with levels of additional laboratory measurements (such as troponins or highly sensitive C-reactive protein) and presence of comorbidities such as diabetes. However, we aimed to investigate NT-proBNP a simple and stand-alone diagnostic tool, and we thus did not add other parameters to the decision whether or not patients should be referred for cardiac work-up. Last, it is likely that our cohort of patients is slightly different than the general obese population. General practitioners may be reluctant to refer a patient for bariatric surgery if they have CV disease such as congestive heart failure or recent myocardial infarction, due to a higher risk of fatal complications following bariatric surgery ^\[^ [@bib33] ^\]^.

Conclusion {#sec5}
==========

Elevated levels of NT-proBNP levels are present in almost one fourth of obese patients aged ≥ 50 years undergoing bariatric surgery. In more than one third of them, there was echocardiographic evidence for LV structural and functional remodeling. Further studies are needed to assess if these preliminary results warrant routine application of NT-proBNP to identify patients at risk for CV complications after bariatric surgery.
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